Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes

Neuroendocrine tumors (NETs) are rare cancers with an associated prolonged survival in some patients. A proportion of patients diagnosed with NETs will present with carcinoid syndrome symptoms, characterized by diarrhea, flushing and/or wheezing. This review summarizes the current treatment options...

Descripción completa

Detalles Bibliográficos
Autores principales: Saavedra, Cristina, Barriuso, Jorge, McNamara, Mairéad G, Valle, Juan W, Lamarca, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690650/
https://www.ncbi.nlm.nih.gov/pubmed/31496810
http://dx.doi.org/10.2147/CMAR.S181439
_version_ 1783443223095541760
author Saavedra, Cristina
Barriuso, Jorge
McNamara, Mairéad G
Valle, Juan W
Lamarca, Angela
author_facet Saavedra, Cristina
Barriuso, Jorge
McNamara, Mairéad G
Valle, Juan W
Lamarca, Angela
author_sort Saavedra, Cristina
collection PubMed
description Neuroendocrine tumors (NETs) are rare cancers with an associated prolonged survival in some patients. A proportion of patients diagnosed with NETs will present with carcinoid syndrome symptoms, characterized by diarrhea, flushing and/or wheezing. This review summarizes the current treatment options for carcinoid syndrome, focusing on the latest novel treatment option, telotristat ethyl. In addition, information on patient-reported outcomes and impact of carcinoid syndrome on quality of life (QOL) and improvement of following treatment with telotristat ethyl are reviewed. This article also provides an overview of the current QOL questionnaires for patients with NETs and addresses unmet needs in this field of patient-reported outcomes.
format Online
Article
Text
id pubmed-6690650
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66906502019-09-06 Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes Saavedra, Cristina Barriuso, Jorge McNamara, Mairéad G Valle, Juan W Lamarca, Angela Cancer Manag Res Review Neuroendocrine tumors (NETs) are rare cancers with an associated prolonged survival in some patients. A proportion of patients diagnosed with NETs will present with carcinoid syndrome symptoms, characterized by diarrhea, flushing and/or wheezing. This review summarizes the current treatment options for carcinoid syndrome, focusing on the latest novel treatment option, telotristat ethyl. In addition, information on patient-reported outcomes and impact of carcinoid syndrome on quality of life (QOL) and improvement of following treatment with telotristat ethyl are reviewed. This article also provides an overview of the current QOL questionnaires for patients with NETs and addresses unmet needs in this field of patient-reported outcomes. Dove 2019-08-08 /pmc/articles/PMC6690650/ /pubmed/31496810 http://dx.doi.org/10.2147/CMAR.S181439 Text en © 2019 Saavedra et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Saavedra, Cristina
Barriuso, Jorge
McNamara, Mairéad G
Valle, Juan W
Lamarca, Angela
Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes
title Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes
title_full Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes
title_fullStr Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes
title_full_unstemmed Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes
title_short Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes
title_sort spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690650/
https://www.ncbi.nlm.nih.gov/pubmed/31496810
http://dx.doi.org/10.2147/CMAR.S181439
work_keys_str_mv AT saavedracristina spotlightontelotristatethylforthetreatmentofcarcinoidsyndromediarrheapatientselectionandreportedoutcomes
AT barriusojorge spotlightontelotristatethylforthetreatmentofcarcinoidsyndromediarrheapatientselectionandreportedoutcomes
AT mcnamaramaireadg spotlightontelotristatethylforthetreatmentofcarcinoidsyndromediarrheapatientselectionandreportedoutcomes
AT vallejuanw spotlightontelotristatethylforthetreatmentofcarcinoidsyndromediarrheapatientselectionandreportedoutcomes
AT lamarcaangela spotlightontelotristatethylforthetreatmentofcarcinoidsyndromediarrheapatientselectionandreportedoutcomes

Ejemplares similares